|
1
|
Siewert JR and Ott K: Are squamous and
adenocarcinomas of the esophagus the same disease? Semin Radiat
Oncol. 17:38–44. 2007. View Article : Google Scholar
|
|
2
|
Lagergren J and Lagergren P: Oesophageal
cancer. BMJ. 341:c62802010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Palucka K and Banchereau J: Cancer
immunotherapy via dendritic cells. Nat Rev Cancer. 12:265–277.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kantoff PW, Higano CS, Shore ND, Berger
ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims
RB, Xu Y, Frohlich MW and Schellhammer PF; IMPACT Study
Investigators. Sipuleucel-T immunotherapy for castration-resistant
prostate cancer. N Engl J Med. 363:411–422. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kato Y: WT1 peptide pulsed dendritic cell
therapy with activated T lymphocytes therapy for advanced cancers.
Gan To Kagaku Ryoho. 37:2240–2242. 2010.(In Japanese).
|
|
6
|
Asakage M, Kitayama J, Tsuno NH, Komuro Y,
Kaisaki S, Hori N, Nagawa H, Tsuno NH, Hori N and Takahashi K:
Primary malignant melanoma of the esophagus treated by
esophagectomy and adjuvant dendritic-cell therapy. J Gastroenterol.
40:545–546. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ueda Y, Shimizu K, Itoh T, Fuji N, Naito
K, Shiozaki A, Yamamoto Y, Shimizu T, Iwamoto A, Tamai H and
Yamagishi H: Induction of peptide-specific immune response in
patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides. Jpn
J Clin Oncol. 37:140–145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kikuchi M, Nakao M, Inoue Y, Matsunaga K,
Shichijo S, Yamana H and Itoh K: Identification of a SART-1-derived
peptide capable of inducing HLA-A24-restricted and tumor-specific
cytotoxic T lymphocytes. Int J Cancer. 81:459–466. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Narita M, Tochiki N, Saitoh A, Watanabe N,
Kaji M, Satoh N, Yamahira A, Nakamura T, Masuko M, Furukawa T, Toba
K, Fuse I, Aizawa Y and Takahashi M: Induction of antigen-specific
cytotoxic T lymphocytes by using monocyte-derived DCs transfected
with in vitro-transcribed WT1 or SART1 mRNA. Med Oncol. 26:429–436.
2009. View Article : Google Scholar
|
|
10
|
Zitvogel L, Regnault A, Lozier A, Wolfers
J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G and
Amigorena S: Eradication of established murine tumors using a novel
cell-free vaccine: dendritic cell-derived exosomes. Nat Med.
4:594–600. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Théry C, Boussac M, Véron P,
Ricciardi-Castagnoli P, Raposo G, Garin J and Amigorena S:
Proteomic analysis of dendritic cell-derived exosomes: a secreted
subcellular compartment distinct from apoptotic vesicles. J
Immunol. 166:7309–7318. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamahira A, Narita M, Nakamura T, Watanabe
N, Kaji M, Taniguchi T, Hashimoto S, Furukawa T, Toba K, Aizawa Y,
Kuzushima K and Takahashi M: Generation of antigen-specific
cytotoxic T lymphocytes using a leukemic plasmacytoid dendritic
cell line as antigen presenting cells. Leuk Res. 35:793–799. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Furukawa T, Koike T, Ying W, Kishi K, Aoki
S, Gotoh T, Hashimoto S, Saitoh H, Hanano M, Shinada S, et al:
Establishment of a new cell line with the characteristics of a
multipotential progenitor from a patient with chronic myelogenous
leukemia in early erythroblastic crisis. Leukemia. 8:171–180.
1994.PubMed/NCBI
|
|
14
|
Shore ND, Mantz CA, Dosoretz DE, Fernandez
E, Myslicki FA, McCoy C, Finkelstein SE and Fishman MN: Building on
sipuleucel-T for immunologic treatment of castration-resistant
prostate cancer. Cancer Control. 20:7–16. 2013.PubMed/NCBI
|
|
15
|
Fujiwara S, Wada H, Miyata H, Kawada J,
Kawabata R, Nishikawa H, Gnjatic S, Sedrak C, Sato E, Nakamura Y,
Sakakibara M, Kanto T, Shimosegawa E, Hatazawa J, Takahashi T,
Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Nakayama E, Mori M
and Doki Y: Clinical trial of the intratumoral administration of
labeled DC combined with systemic chemotherapy for esophageal
cancer. J Immunother. 35:513–521. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Milano F and Krishnadath KK: Novel
therapeutic strategies for treating esophageal adenocarcinoma: the
potential of dendritic cell immunotherapy and combinatorial
regimens. Hum Immunol. 69:614–624. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kono K, Iinuma H, Akutsu Y, Tanaka H,
Hayashi N, Uchikado Y, Noguchi T, Fujii H, Okinaka K, Fukushima R,
Matsubara H, Ohira M, Baba H, Natsugoe S, Kitano S, Takeda K,
Yoshida K, Tsunoda T and Nakamura Y: Multicenter, phase II clinical
trial of cancer vaccination for advanced esophageal cancer with
three peptides derived from novel cancer-testis antigens. J Transl
Med. 10:1412012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Théry C, Ostrowski M and Segura E:
Membrane vesicles as conveyors of immune responses. Nat Rev
Immunol. 9:581–593. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hao S, Bai O, Li F, Yuan J, Laferte S and
Xiang J: Mature dendritic cells pulsed with exosomes stimulate
efficient cytotoxic T-lymphocyte responses and antitumour immunity.
Immunology. 120:90–102. 2007. View Article : Google Scholar
|
|
20
|
Taieb J, Chaput N, Schartz N, Roux S,
Novault S, Ménard C, Ghiringhelli F, Terme M, Carpentier AF,
Darrasse-Jèze G, Lemonnier F and Zitvogel L: Chemoimmunotherapy of
tumors: cyclophosphamide synergizes with exosome based vaccines. J
Immunol. 176:2722–2729. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dai S, Wei D, Wu Z, Zhou X, Wei X, Huang H
and Li G: Phase I clinical trial of autologous ascites-derived
exosomes combined with GM-CSF for colorectal cancer. Mol Ther.
16:782–790. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Escudier B, Dorval T, Chaput N, André F,
Caby MP, Novault S, Flament C, Leboulaire C, Borg C, Amigorena S,
Boccaccio C, Bonnerot C, Dhellin O, Movassagh M, Piperno S, Robert
C, Serra V, Valente N, Le Pecq JB, Spatz A, Lantz O, Tursz T,
Angevin E and Zitvogel L: Vaccination of metastatic melanoma
patients with autologous dendritic cell (DC) derived-exosomes:
results of the first phase I clinical trial. J Transl Med.
3:102005. View Article : Google Scholar
|
|
23
|
Morse MA, Garst J, Osada T, Khan S,
Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A,
Hsu DH, Le Pecq JB and Lyerly HK: A phase I study of dexosome
immunotherapy in patients with advanced non-small cell lung cancer.
J Transl Med. 3:92005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Berntsen A, Trepiakas R, Wenandy L,
Geertsen PF, thor Straten P, Andersen MH, Pedersen AE, Claesson MH,
Lorentzen T, Johansen JS and Svane IM: Therapeutic dendritic cell
vaccination of patients with metastatic renal cell carcinoma: a
clinical phase 1/2 trial. J Immunother. 31:771–780. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Trepiakas R, Berntsen A, Hadrup SR, Bjørn
J, Geertsen PF, Straten PT, Andersen MH, Pedersen AE, Soleimani A,
Lorentzen T, Johansen JS and Svane IM: Vaccination with autologous
dendritic cells pulsed with multiple tumor antigens for treatment
of patients with malignant melanoma: results from a phase I/II
trial. Cytotherapy. 12:721–734. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Svane IM, Pedersen AE, Johnsen HE, Nielsen
D, Kamby C, Gaarsdal E, Nikolajsen K, Buus S and Claesson MH:
Vaccination with p53-peptide-pulsed dendritic cells, of patients
with advanced breast cancer: report from a phase I study. Cancer
Immunol Immunother. 53:633–641. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ellebaek E, Engell-Noerregaard L, Iversen
TZ, Froesig TM, Munir S, Hadrup SR, Andersen MH and Svane IM:
Metastatic melanoma patients treated with dendritic cell
vaccination, Interleukin-2 and metronomic cyclophosphamide: results
from a phase II trial. Cancer Immunol Immunother. 61:1791–1804.
2012. View Article : Google Scholar : PubMed/NCBI
|
